Year :
2020
| Month :
September
| Volume :
14
| Issue :
9
| Page :
EE05 - EE09
Full Version
Utility of TP53 in Breast Carcinoma Immunophenotypes
Published: September 1, 2020 | DOI: https://doi.org/10.7860/JCDR/2020/44743.14049
Ria Jaggi, Samarth Shukla, Sourya Acharya, Sunita Vagha
1. Postgraduate, Department of Pathology, Jawaharlal Nehru Medical College, DMIMS University, Wardha, Maharashtra, India.
2. Professor, Department of Pathology, Jawaharlal Nehru Medical College, DMIMS University, Wardha, Maharashtra, India.
3. Professor, Department of Medicine, Jawaharlal Nehru Medical College, DMIMS University, Wardha, Maharashtra, India.
4. Professor, Department of Pathology, Jawaharlal Nehru Medical College, DMIMS University, Wardha, Maharashtra, India.
Correspondence Address :
Dr. Ria Jaggi,
Department of Pathology, Jawaharlal Nehru Medical College, DMIMS University, Wardha, Maharashtra, India.
E-mail: rhiyaj27@gmail.com
Abstract
Breast cancer is a heterogeneous disease and has significant variability in presentation, treatment response, and prognosis. The management of carcinoma breast is currently based on immunophenotypes and Tumour Nodes Metastasis (TNM) staging. The aim of the study is to review the literature and to look for treatment guidelines of carcinoma breast, the role of immunophenotypes in treatment of carcinoma breast, TP53 mutation in breast cancer, and the relationship of TP53 mutation with immunophenotypes, histological grade, efficacy of chemotherapy, and BRCA (Breast Cancer gene) mutation. Pubmed database was researched and a total of 510 articles were analysed. A total of one meta-analysis, one randomised controlled trial, one literature review, nine prospective studies, and three retrospective studies were included for further analysis. It was observed that TP53 mutation is associated with poor overall survival. It was also found to be inversely associated with the Estrogen Receptor (ER) status and so it was seen more commonly in basal type and HER2/neu enriched breast cancer. There is a need for further studies to establish the definite association between TP53 and immunophenotypes so that TP53 alone can be used as a guide for management in carcinoma breast at low resource centres.
Keywords
Blood richardson grade, Guardian of the genome, HER2/neu enriched, Molecular classification,
Estrogen receptor, Progesterone receptor, Tumour suppressor gene
DOI: 10.7860/JCDR/2020/44743.14049
Date of Submission: Apr 23, 2020
Date of Peer Review: May 27, 2020
Date of Acceptance: Jul 25, 2020
Date of Publishing: Sep 01, 2020
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? NA
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Apr 24, 2020
• Manual Googling: Jul 23, 2020
• iThenticate Software: Aug 27, 2020 (10%)
ETYMOLOGY: Author Origin
|